Novo Nordisk Foundation's BioInnovation Institute has funded seven new projects with debt financing and grants to progress research in areas like male infertility and stem cell therapies.
BioInnovation Institute (BII), a life sciences incubator run by pharmaceutical firm Novo’s research endowment, Novo Nordisk Foundation, has accepted seven projects into its latest cohort.
The batch consists of four startups and three research programmes from around Europe, and their target sectors include drug development, health and bioindustrial technology.
The startups include stem cell therapy developer and Karolinska Institute spinout Boost Pharma, cell fermentation technology developer Enduro Genetics and Kesmalea Therapeutics, a producer of protein degrader compounds, as well as…
